Effects of Dendrimer-Like Biopolymers on Physical Stability of Amorphous Solid Dispersions and Drug Permeability Across Caco-2 Cell Monolayers
The potential applications of dendrimer-like biopolymers (DLB) as stabilizing excipients for amorphous solid dispersion (ASD) of niclosamide, celecoxib, and resveratrol were evaluated based on (1) the formation and physical stability of the ASD and (2) the permeability and flux of the agents across...
Gespeichert in:
Veröffentlicht in: | AAPS PharmSciTech 2018-08, Vol.19 (6), p.2459-2471 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The potential applications of dendrimer-like biopolymers (DLB) as stabilizing excipients for amorphous solid dispersion (ASD) of niclosamide, celecoxib, and resveratrol were evaluated based on (1) the formation and physical stability of the ASD and (2) the permeability and flux of the agents across Caco-2 cell monolayers. The evaluation was made by comparing the performance of prototype phytoglycogen derivatives (DLB1, DLB2, and DLB3) with commonly used polymers such as HPMCAS, PVPVA, and Soluplus®. PXRD was used to confirm the formation of the dispersions and detect crystallinity peaks formed during 2- and 4-week storage at 40°C/75% RH. At concentrations below 2 g/mL, the viability of Caco-2 cells remained above 80% for all DLB samples compared to untreated cells in the MTT assay. Permeability studies revealed a repeating pattern in which an increase in the initial concentration (
C
0
) was associated with a concomitant decrease in the apparent permeability (
P
app
) which we theorize is due to differences in drug-polymer interactions. Niclosamide-DLB1 dispersion had the lowest flux due to a significant reduction in
P
app
. The high increase in the
C
0
of celecoxib-DLB2, however, made up for the reduction in the
P
app
and produced the highest flux values compared to other polymers. Resveratrol-DLB3 had a 5× reduction in
P
app
, but
C
0
increased from 25.8 to 176 μg/mL led to a higher flux compared to the crystalline drug without polymer. Collectively, these results provide a “proof-of-concept” basis to demonstrate that DLB excipients have the ability to increase apparent solubility (Sol
app
), most likely due to drug-binding capacity. |
---|---|
ISSN: | 1530-9932 1530-9932 |
DOI: | 10.1208/s12249-018-1080-6 |